The volume of biopharmaceuticals reaching the clinic continues to increase, and these products now account for an estimated 40 percent of the overall pharmaceutical pipeline, according to a recent report from industry consultants BioPlan Associates. Monoclonal antibodies (mAbs) are currently amongst the largest of the different classes of biotherapeutic products, with their success driven in…